HUE036094T2 - Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek - Google Patents

Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek

Info

Publication number
HUE036094T2
HUE036094T2 HUE11818884A HUE11818884A HUE036094T2 HU E036094 T2 HUE036094 T2 HU E036094T2 HU E11818884 A HUE11818884 A HU E11818884A HU E11818884 A HUE11818884 A HU E11818884A HU E036094 T2 HUE036094 T2 HU E036094T2
Authority
HU
Hungary
Prior art keywords
cells expressing
cytolytic properties
cytolytic
properties
expressing
Prior art date
Application number
HUE11818884A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of HUE036094T2 publication Critical patent/HUE036094T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
HUE11818884A 2010-08-20 2011-08-22 Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek HUE036094T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US201161495055P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
HUE036094T2 true HUE036094T2 (hu) 2018-06-28

Family

ID=45594250

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11818884A HUE036094T2 (hu) 2010-08-20 2011-08-22 Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek

Country Status (19)

Country Link
US (3) US20120045423A1 (enExample)
EP (1) EP2606125B1 (enExample)
JP (2) JP6408219B2 (enExample)
KR (1) KR101900807B1 (enExample)
CN (2) CN108245673A (enExample)
AU (1) AU2011291477B2 (enExample)
BR (1) BR112013003989B1 (enExample)
CA (1) CA2808873C (enExample)
DK (1) DK2606125T3 (enExample)
ES (1) ES2660577T3 (enExample)
HU (1) HUE036094T2 (enExample)
IL (1) IL224813B (enExample)
NO (1) NO2606125T3 (enExample)
PH (1) PH12013500519B1 (enExample)
PL (1) PL2606125T3 (enExample)
PT (1) PT2606125T (enExample)
SG (2) SG187846A1 (enExample)
TR (1) TR201802334T4 (enExample)
WO (1) WO2012024666A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036094T2 (hu) 2010-08-20 2018-06-28 Immunovative Therapies Ltd Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
TWI739740B (zh) 2015-04-22 2021-09-21 德商奎爾法克股份有限公司 用於治療腫瘤疾病之含有rna的組成物
JP7039623B2 (ja) 2017-05-26 2022-03-22 グリーン・クロス・ラブ・セル・コーポレイション 形質転換されたt細胞を用いてナチュラルキラー細胞を培養する方法
SG11202104662UA (en) 2018-11-14 2021-06-29 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t-cells
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030175242A1 (en) 2001-09-17 2003-09-18 Micheal Gruenberg Cell therapy system
AU2003260452A1 (en) 2002-08-23 2004-03-11 Gabriele Multhoff Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ, リミテッド 細胞治療のためのt細胞を調製するための方法
HUE036094T2 (hu) 2010-08-20 2018-06-28 Immunovative Therapies Ltd Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek

Also Published As

Publication number Publication date
ES2660577T3 (es) 2018-03-23
PH12013500519B1 (en) 2020-06-26
SG10201510524TA (en) 2016-01-28
CA2808873C (en) 2020-02-18
US20130196428A1 (en) 2013-08-01
IL224813B (en) 2020-06-30
JP6408219B2 (ja) 2018-10-17
KR101900807B1 (ko) 2018-11-08
CN103068973A (zh) 2013-04-24
KR20130103485A (ko) 2013-09-23
EP2606125A2 (en) 2013-06-26
BR112013003989A2 (pt) 2017-11-14
EP2606125A4 (en) 2014-03-19
JP2017061558A (ja) 2017-03-30
EP2606125B1 (en) 2017-11-22
NO2606125T3 (enExample) 2018-04-21
CA2808873A1 (en) 2012-02-23
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
JP6525946B2 (ja) 2019-06-05
WO2012024666A2 (en) 2012-02-23
PT2606125T (pt) 2018-02-27
US20120045423A1 (en) 2012-02-23
US20130195825A1 (en) 2013-08-01
TR201802334T4 (tr) 2018-03-21
AU2011291477B2 (en) 2016-07-28
DK2606125T3 (en) 2018-03-05
PH12013500519A1 (en) 2013-05-06
BR112013003989B1 (pt) 2020-11-24
SG187846A1 (en) 2013-03-28
PL2606125T3 (pl) 2018-05-30
JP2013536232A (ja) 2013-09-19
AU2011291477A1 (en) 2013-04-04
CN108245673A (zh) 2018-07-06

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
IL221511A (en) Arilatriazolones associated with bis aryl and their use
SI2606120T1 (sl) Človeške facilitacijske celice in njihova uporaba
ZA201208173B (en) Peptices and their use
HUE045845T2 (hu) Módosított relaxin polipeptidek és felhasználásuk
HUE057004T2 (hu) CD277 elleni antitestek és alkalmazásaik
BR112012031855A2 (pt) composição e artigo
IL232262A (en) Therapeutic agents and uses thereof
BR112012027165A2 (pt) composição e artigo
HUE036535T2 (hu) Polietilén-glikol alapú adrenomedullin elõvegyület és alkalmazása
HUE053623T2 (hu) Vegyületek és azok felhasználása
HUE036094T2 (hu) Th1 jellemzõket és citolítikus tulajdonságokat expresszáló sejtek
EP3039162A4 (en) Determination of immune cells and other cells
IL245272B (en) pif-transfected cells and methods of use
IL222343A0 (en) Compositions comprising allogeneic th1 cells and uses thereof
HUE037040T2 (hu) Rezveratrol és karboximetil-glükán asszociátuma
DE11786796T8 (de) Antigenpeptid und verwendung davon
IL233961A0 (en) The composition of a phytogenic supplement and methods of its use
GB201211903D0 (en) Artificial eyes and manufacture thereof
GB201223374D0 (en) Personal care composition and methods of making the same
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
GB201006380D0 (en) Excipients and their use
SG10201506940UA (en) Thioesterases and their use
ES1072633Y (es) Mosquero evolucionado y mejorado